In a groundbreaking shift for women’s health, the long-recognised term polycystic ovary syndrome (PCOS) is being replaced with polyendocrine metabolic ovarian syndrome (PMOS). This monumental change, hailed as the most extensive global engagement effort in health naming history, aims to reshape the understanding and treatment of a condition that affects approximately one in eight women worldwide. The new designation reflects a deeper comprehension of the condition’s complexities, encompassing a range of metabolic and hormonal disturbances that extend far beyond mere ovarian cysts.
The Rationale Behind the Change
The previous designation of PCOS has long been deemed misleading. Contrary to its name, the condition is not primarily characterised by the presence of cysts; rather, it involves follicles surrounding partially developed eggs. These are the result of hormonal disruptions that hinder normal ovarian development.
For many years, the misnomer contributed to a significant lack of awareness and understanding of the condition. This confusion has led to underdiagnosis and inadequate treatment, leaving countless women struggling with symptoms that range from infertility and pregnancy complications to mental health challenges. As Professor Helena Teede, an endocrinologist at Monash University and a leading advocate for the change, pointed out, “PMOS builds on what we knew before but reflects the much more diverse and broad features of this condition.”
A Collaborative Effort for Change
The transition from PCOS to PMOS has been the result of over a decade of advocacy and collaboration. Spearheaded by a diverse team of health professionals, researchers, and patients, this initiative has been described as an unprecedented global engagement process. In 2025, a survey revealed that an overwhelming 85.6% of patients and 76.1% of healthcare professionals supported the name change. With 22,000 participants contributing their voices and insights, including the involvement of 56 leading organisations, the push to retire the acronym PCOS gained considerable traction.
Robyn Vettese, chair of the PMOS Patient Advisory Council in Alberta, expressed optimism regarding the name change, stating, “This new name reflects the condition as a complex and cyclical metabolic disorder, which we hope will help patients receive the understanding and support they deserve.”
The Fight Against Stigma
One of the primary goals of the renaming effort is to dismantle the stigma surrounding PMOS. Women often face judgement regarding weight gain and other symptoms associated with the condition, such as anxiety, depression, and increased risk of metabolic disorders like Type 2 diabetes. The new terminology aims to foster a better understanding of PMOS as a multifaceted disorder rather than a singular ovarian issue.
This shift in perception is vital, as many women suffer in silence, overwhelmed by the myriad of complications that can affect their physical and mental health. By reframing the conversation around PMOS, the hope is to create a more supportive environment where women can seek the care they need without fear of stigma.
Looking Ahead: The Future of PMOS Research and Care
As the name change takes effect, the focus will shift towards improving education and advocacy around PMOS. Experts, including Dr. Jamie Benham from the University of Calgary, emphasise the importance of increasing awareness and funding for research into this condition. The 2024 McKinsey Health Institute report, “Closing the Women’s Health Gap,” highlighted the urgent need for improved diagnosis and treatment options for PMOS, which has historically been neglected.
In the coming years, healthcare providers across various specialities, including endocrinology, gynecology, and dermatology, are expected to enhance their understanding and management of PMOS. This renewed focus represents not merely a change in nomenclature but a commitment to delivering comprehensive care that acknowledges the complexity of this condition.
Why it Matters
The renaming of PCOS to PMOS marks a significant step forward in women’s health, reflecting a more nuanced understanding of a condition that affects millions. By prioritising accurate terminology and fostering collaboration among health professionals and patients, the hope is to promote better awareness, more effective treatments, and ultimately, a higher quality of life for those living with PMOS. This initiative is not just about a name; it represents a transformative journey towards recognition, respect, and improved care for women everywhere.
